Mouse PD-L1/B7-H1 PicoKine ELISA Kit
To Order Contact us: [email protected]
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8598-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8598SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8640-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8640-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8640SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8641-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8641-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8641SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V9155-100UG | NSJ Bioreagents | 100ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V9155-20UG | NSJ Bioreagents | 20ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V9155SAF-100UG | NSJ Bioreagents | 100ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V3955-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V3955-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V3955BTN | NSJ Bioreagents | 500 ul | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V3955PE-100T | NSJ Bioreagents | 100 Tests | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V3955SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7822-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7822-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7822SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7823-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7823-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7823SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7974-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7974-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7974SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7988-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7988-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7988SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8009-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8009-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8009SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8067-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8067-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
|||
V8067SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
Recombinant Mouse PD-L1/B7-H1 Protein |
|||
RP01149 | Abclonal | 10 μg | EUR 186 |
Recombinant Mouse PD-L1/B7-H1 Protein |
|||
RP01158 | Abclonal | 20 μg | EUR 219.6 |
ELISA kit for Human PD-L1/B7-H1 |
|||
EK5678 | SAB | 96 tests | EUR 663.6 |
Description: Enzyme-linked immunosorbent assay kit for quantification of Human PD-L1/B7-H1 in samples from serum, plasma, tissue homogenates and other biological fluids. |
QuickDetect? PD-L1/B7-H1 (Human) ELISA Kit |
|||
K4416-100 | Biovision | each | EUR 1096.8 |
CD274 [B7-H1/PD-L1] Recombinant Protein |
|||
90-429 | ProSci | 100 ug | EUR 651.3 |
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
CD274 [B7-H1/PD-L1] Recombinant Protein |
|||
90-431 | ProSci | 100 ug | EUR 651.3 |
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
Anti-PD-L1/B7-H1/CD274 Antibody |
|||
A00109 | BosterBio | 100ug/vial | EUR 352.8 |
Polyclonal B7-H1 / PD-L1 / CD274 Antibody |
|||
APR03374G | Leading Biology | 0.05ml | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human B7-H1 / PD-L1 / CD274 . This antibody is tested and proven to work in the following applications: |
PD-L1/B7-H1/CD274 (C-mFc) |
|||
E21-M06 | EnoGene | 10ug | EUR 411.6 |
PD-L1/B7-H1/CD274 (C-Flag) |
|||
E21-M33 | EnoGene | 10ug | EUR 411.6 |
PD-L1/B7-H1/CD274(Fc fusion) |
|||
E21-M79 | EnoGene | 10ug | EUR 411.6 |
Recombinant Human PD-L1/B7-H1 Protein |
|||
RP00068 | Abclonal | 5 μg | EUR 163.2 |
Recombinant Human PD-L1/B7-H1 Protein |
|||
RP00184 | Abclonal | 10 μg | EUR 178.8 |
Recombinant Mouse PD-L1/B7-H1/CD274 (C-6His) |
|||
CJ88-10ug | Novoprotein | 10ug | EUR 120 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L1/B7-H1/CD274 (C-6His) |
|||
CJ88-1mg | Novoprotein | 1mg | EUR 1338 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L1/B7-H1/CD274 (C-6His) |
|||
CJ88-500ug | Novoprotein | 500ug | EUR 850.8 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L1/B7-H1/CD274 (C-6His) |
|||
CJ88-50ug | Novoprotein | 50ug | EUR 187.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L1/B7-H1/CD274 (C-Fc) |
|||
CJ89-10ug | Novoprotein | 10ug | EUR 120 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L1/B7-H1/CD274 (C-Fc) |
|||
CJ89-1mg | Novoprotein | 1mg | EUR 1338 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L1/B7-H1/CD274 (C-Fc) |
|||
CJ89-500ug | Novoprotein | 500ug | EUR 850.8 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Mouse PD-L1/B7-H1/CD274 (C-Fc) |
|||
CJ89-50ug | Novoprotein | 50ug | EUR 187.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Human CellExp? PD-L1 /CD274 /B7-H1, mouse recombinant |
|||
7428-10 | Biovision | each | EUR 333.6 |
Human CellExp? PD-L1 /CD274 /B7-H1, mouse recombinant |
|||
7428-50 | Biovision | each | EUR 861.6 |
PD-L1 / B7-H1 (19-134) Recombinant Protein |
|||
11-114 | ProSci | 0.1 mg | EUR 714.3 |
Description: Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. |
Recombinant Rat PD-L1/B7-H1/CD274 Protein |
|||
RP00800 | Abclonal | 10 μg | EUR 208.8 |
CD274 [B7-H1/PD-L1] non-lytic Recombinant Protein |
|||
90-430 | ProSci | 100 ug | EUR 651.3 |
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
CD274 [B7-H1/PD-L1] non-lytic Recombinant Protein |
|||
90-432 | ProSci | 100 ug | EUR 651.3 |
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
Recombinant Human PD-L1/B7-H1/CD274 (C-mFc) |
|||
CM06-10ug | Novoprotein | 10ug | EUR 138 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-mFc) |
|||
CM06-1mg | Novoprotein | 1mg | EUR 2008.8 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-mFc) |
|||
CM06-500ug | Novoprotein | 500ug | EUR 1423.2 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-mFc) |
|||
CM06-50ug | Novoprotein | 50ug | EUR 242.4 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-Flag) |
|||
CM33-10ug | Novoprotein | 10ug | EUR 138 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB 150mM Nacl pH 7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-Flag) |
|||
CM33-1mg | Novoprotein | 1mg | EUR 2008.8 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB 150mM Nacl pH 7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-Flag) |
|||
CM33-500ug | Novoprotein | 500ug | EUR 1423.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB 150mM Nacl pH 7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-Flag) |
|||
CM33-50ug | Novoprotein | 50ug | EUR 242.4 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB 150mM Nacl pH 7.4. |
Recombinant Human PD-L1/B7-H1/CD274(C-Fc) |
|||
CM79-10ug | Novoprotein | 10ug | EUR 138 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4. |
Recombinant Human PD-L1/B7-H1/CD274(C-Fc) |
|||
CM79-1mg | Novoprotein | 1mg | EUR 2008.8 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4. |
Recombinant Human PD-L1/B7-H1/CD274(C-Fc) |
|||
CM79-500ug | Novoprotein | 500ug | EUR 1423.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4. |
Recombinant Human PD-L1/B7-H1/CD274(C-Fc) |
|||
CM79-50ug | Novoprotein | 50ug | EUR 242.4 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-6His) |
|||
C315-10ug | Novoprotein | 10ug | EUR 108 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Trehalose, pH 7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-6His) |
|||
C315-1mg | Novoprotein | 1mg | EUR 1399.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Trehalose, pH 7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-6His) |
|||
C315-500ug | Novoprotein | 500ug | EUR 997.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Trehalose, pH 7.4. |
Recombinant Human PD-L1/B7-H1/CD274 (C-6His) |
|||
C315-50ug | Novoprotein | 50ug | EUR 205.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Trehalose, pH 7.4. |
PD-L1 Antibody / B7-H1 / CD274 (C-Terminal Region) |
|||
F54219-0.05ML | NSJ Bioreagents | 0.05 ml | EUR 165 |
PD-L1 Antibody / B7-H1 / CD274 (C-Terminal Region) |
|||
F54219-0.2ML | NSJ Bioreagents | 0.2 ml | EUR 379 |
Human CellExp? PD-L1 /CD274 /B7-H1, human recombinant |
|||
7429-10 | Biovision | each | EUR 268.8 |
Human CellExp? PD-L1 /CD274 /B7-H1, human recombinant |
|||
7429-1000 | Biovision | each | Ask for price |
Human CellExp? PD-L1 /CD274 /B7-H1, human recombinant |
|||
7429-250 | Biovision | each | EUR 2590.8 |
Human CellExp? PD-L1 /CD274 /B7-H1, human recombinant |
|||
7429-50 | Biovision | each | EUR 724.8 |
Anti-PD-L1 (CD274) (B7-H1), Rabbit Monoclonal Antibody |
|||
A1824-50 | Biovision | each | Ask for price |
Mouse PD-L1/B7-H1 EZ-Set™ ELISA Kit (DIY Antibody Pairs) |
|||
EZ1450 | BosterBio | 5 plates/kit | EUR 388.8 |
Description: NA |
Human Programmed Death Ligand 1 ELISA Kit (PD-L1/B7-H1/ CD274) |
|||
RK04115 | Abclonal | 96 Tests | EUR 727.2 |
PD-L1 / PDCD1LG1 / CD274 / B7-H1; Clone PDL1/2746 (Concentrate) |
|||
RA0501-C.1 | ScyTek Laboratories | 0.1 ml | EUR 150 |
PD-L1 / PDCD1LG1 / CD274 / B7-H1; Clone PDL1/2746 (Concentrate) |
|||
RA0501-C.5 | ScyTek Laboratories | 0.5 ml | EUR 360 |
PD-L1 / PDCD1LG1 / CD274 / B7-H1; Clone PDL1/2746 (Concentrate) |
|||
RA0501-C1 | ScyTek Laboratories | 1 ml | EUR 600 |
Programmed death ligand 1 Antibody / Pd-l1 / B7-h1 / Cd274 |
|||
RQ6346 | NSJ Bioreagents | 100 ug | EUR 419 |
Description: Programmed death-ligand 1 (PD-L1), also known as CD274 or B7-H1, is a protein that in humans is encoded by the CD274 gene. It is mapped to 9p24.1. PD-L1 is a 40kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. It has been concluded that upregulation of PD-L1 on tumor MDCs downregulates T-cell immunity and that PD-L1 blockade may represent an approach for cancer immunotherapy. Additionally, PD-L1 can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. What�s more, it has been found that PD1/PDL1 pathway may be a good target for restoring antitumor immunity in ovarian cancer. |
Human PD-L2/B7-DC PicoKine ELISA Kit |
|||
EK1447 | BosterBio | 96 wells | EUR 510 |
Description: For Quantitative Detection of human PD-L2 in cell culture supernates, serum and plasma (heparin, EDTA). |
Rat Anti-Mouse PD-L1 (B7-H1) Monoclonal antibody, clone 10F.9G2 |
|||
CABT-L4404-1mg | Creative Diagnostics | 1 mg | EUR 1076.4 |
Rat Anti-Mouse PD-L1 (B7-H1) Monoclonal antibody, clone 10F.9G2 |
|||
CABT-L4404-5mg | Creative Diagnostics | 5 mg | EUR 2886 |
Mouse Anti-Human PD-L1 (B7-H1) Monoclonal antibody, clone 29E.2A3 |
|||
CABT-L4518-1mg | Creative Diagnostics | 1 mg | EUR 1076.4 |
Mouse Anti-Human PD-L1 (B7-H1) Monoclonal antibody, clone 29E.2A3 |
|||
CABT-L4518-5mg | Creative Diagnostics | 5 mg | EUR 2886 |
Anti-PD-L1 (CD274) (B7-H1) Rabbit Monoclonal Antibody, Clone#RM320 |
|||
M00109-1 | BosterBio | 100uL | EUR 512.4 |
Description: Anti-PD-L1 (CD274) (B7-H1) Rabbit Monoclonal Antibody, Clone#RM320 tested in WB, IHC, reactive to Human |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC042746-100 | Biotium | 100uL | EUR 279.6 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC042746-500 | Biotium | 500uL | EUR 654 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCA2746-250 | Biotium | 250uL | EUR 472.8 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), APC conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCAP2746-100 | Biotium | 100uL | EUR 279.6 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCAP2746-500 | Biotium | 500uL | EUR 654 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCH2746-100 | Biotium | 100uL | EUR 279.6 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCH2746-500 | Biotium | 500uL | EUR 654 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCP2746-250 | Biotium | 250uL | EUR 472.8 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), PerCP conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC942746-100 | Biotium | 100uL | EUR 279.6 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC942746-500 | Biotium | 500uL | EUR 654 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC812746-100 | Biotium | 100uL | EUR 279.6 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC812746-500 | Biotium | 500uL | EUR 654 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCR2746-250 | Biotium | 250uL | EUR 472.8 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), RPE conjugate, Concentration: 0.1mg/mL |
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCB2746-100 | Biotium | 100uL | EUR 279.6 |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Biotin conjugate, Concentration: 0.1mg/mL |